Enlivex Ltd. (FRA:1BT)
Germany · Delayed Price · Currency is EUR | Market Cap | 216.35M +880.6% |
| Revenue (ttm) | n/a |
| Net Income | 1.05B |
| EPS | 21.70 |
| Shares Out | n/a |
| PE Ratio | 0.21 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | n/a |
| Open | 0.9350 |
| Previous Close | 1.0000 |
| Day's Range | 0.9350 - 0.9350 |
| 52-Week Range | 0.5900 - 1.7100 |
| Beta | n/a |
| RSI | 50.48 |
| Earnings Date | Mar 30, 2026 |
About Enlivex
Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee osteoarthritis. The company also develops 0189-22-KMC, which is in phase I/II clinical trial to treat end-stage knee osteoarthritis; 0006-24-KMC, which is in phase I... [Read more]
News
Enlivex Rain Update: Rain Launches an OpenClaw and AI Agent Interface Allowing Anyone To Create A Prediction Market Via A Single Prompt
According to the Rain Foundation, anyone using OpenClaw or other AI agents can generate a live prediction market via a single prompt to the agent, without manual coding or centralized gatekeepers ...
Enlivex Reports Full-Year 2025 Results: Profit (Net Income) of $1.23 Billion and Diluted Earnings Per Share (EPS) of $25.48
Earnings Driven by Treasury and Treasury-Related Asset Appreciation Nes-Ziona, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV; “Enlivex” or “the Company”) today reported financi...
Enlivex Announces $21 Million Debt Financing, Decentralized Prediction Markets RAIN Token-Related Updates and $20 Million Share Repurchase Program
$21 Million debt financing, convertible to ENLV ordinary shares at fixed $2.69175 per share, a 264% premium to the Nasdaq closing price on March 20, 2026, with a single institutional investor The Comp...
Quality Longevity Company Enlivex Receives Investigational New Drug (IND) Clearance from the FDA for Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
Enlivex's first regulatory approval for a late-stage global Phase 2b study in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis following the implementation of its dual-engine value creation ...
Enlivex Treasury Portfolio Update: New Listing of the RAIN Token on Kraken, the Second-Largest U.S. Cryptocurrency Exchange
Additional exchange listing expected to increase token access and contribute to expanded secondary market liquidity for RAIN Nes-Ziona, Israel, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Enlivex Therapeutics L...
Enlivex Treasury Portfolio Update: Listing of the RAIN Token on WhiteBIT, a Leading Cryptocurrency Exchange
Listing expected to expand market access and secondary liquidity for Enlivex's primary digital treasury asset Nes-Ziona, Israel, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: EN...
Enlivex Therapeutics Shares to Trade Exclusively on Nasdaq
Voluntarily Delisting of Ordinary Shares from Trading on the Tel Aviv Stock Exchange to Promote U.S.-Based Trading, Reduce Administrative Costs of Dual Listing
Analyst Sees Massive Upside For Penny Stock Enlivex After RAIN Token Gains Momentum
In January, Enlivex Therapeutics Ltd. (NASDAQ: ENLV) reported that its treasury asset, the RAIN token, had been listed on the KuCoin cryptocurrency exchange effective January 6.
Enlivex Management to Host Fireside Chat on December 11 to Discuss RAIN Token Strategy and Allocetra Clinical Development
Nes-Ziona, Israel, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, “Enlivex” or “the Company”), today announced that it will host a virtual fireside chat on Thursday, Decemb...
Enlivex Appoints former Italy Prime Minister Matteo Renzi to Board of Directors
Enlivex Announced today $212,000,000 private placement to initiate world's first prediction markets digital asset treasury strategy, via RAIN token accumulation NESS ZIONA, Israel , Nov. 24, 2025 /PRN...
Enlivex Announces $212,000,000 Private Placement to Initiate World's First Prediction Markets Digital Asset Treasury Strategy, via RAIN token Accumulation, and the Appointment of Matteo Renzi, Former Prime Minister of Italy, to its Board
- Upon the closing of the private placement, Enlivex will adopt the world's first RAIN prediction markets token digital asset treasury strategy, via RAIN token accumulation. - RAIN is a fully decentra...
Enlivex Announces Positive 6-Month Topline Data –Demonstrating Durable and Persistent Pain Reduction and Improved Function in Primary Age-Related Patients with Moderate to Severe Knee Osteoarthritis
Nes-Ziona, Israel, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. ( Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced positive...
Enlivex Therapeutics to Present Phase IIa 3-month Data of Allocetra in Patients with Moderate-to-Severe Knee Osteoarthritis at the ACR Convergence 2025
Ness-Ziona, Israel, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that it ...
D. Boral Capital to Host KOL Webinar With World Leading Experts Featuring Insights & Breakthroughs from Enlivex's Knee Osteoarthritis Program
Nes-Ziona, Israel, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, will participate in a li...
Enlivex CEO Issues Letter to Shareholders Outlining Strategic Roadmap Following Positive Phase IIa Allocetra™ Results
Allocetra™ demonstrated statistically significant and clinically meaningful improvements in pain and function in Phase IIa trial in primary osteoarthritis patients Six-month data expected Novemb...
Enlivex Announces Issuance of New Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis
Nes-Ziona, Israel, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd.
Enlivex Announces Positive Topline Data From Multi-Country, Randomized, Controlled, Phase I/II Trial Evaluating Allocetra in Patients With Moderate-To-Severe Knee Osteoarthritis
ENX-CL-05-001 Trial: 3-months topline data - In the overall modified intention-to-treat (mITT) population, improvements across all efficacy and secondary endpoints, including 24% reduction in knee p...
Enlivex to Present 3-Month Topline Data from Phase IIa Moderate/Severe Knee Osteoarthritis Trial on August 18 Webinar
Webinar to Review Results from Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Allocetra™ in Patients with Moderate to Severe Knee Osteoarthritis Nes-Ziona, Israel, Aug. 14...
Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II Topline Data
Nes-Ziona, Israel, July 28, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that all ...
Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of Rheumatology
Ness-Ziona, Israel, June 10, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that it ...
Enlivex Selected to Present at Israeli BioMed 2025 Conference
Presentation to highlight Allocetra™ and the therapeutic potential of macrophage reprogramming in inflammatory diseases Ness-Ziona, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (...
Enlivex Therapeutics to Showcase Allocetra's Potential in Osteoarthritis at OARSI 2025 World Congress
Presentations to underscore AllocetraTM's novel mechanism targeting immune imbalance in joint disease Ness-Ziona, Israel, April 23, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, th...
Enlivex Announces Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluating Allocetra In Patients With Moderate To Severe Knee Osteoarthritis
Nes-Ziona, Israel, April 21, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the...
Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis
Temporomandibular joint (TMJ) osteoarthritis is a degenerative, debilitating and progressive disease, the second most common musculoskeletal condition affecting five to 12% of the population globally ...
Enlivex Receives Notice of Allowance for Chinese Patent Application Covering the Use of Allocetra in Patients with Osteoarthritis
Nes-Ziona, Israel, March 17, 2025 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the...